Compare JPMorgan Equity Premium Income ETF (JEPI) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Koninklijke Philips NV — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.85, while Koninklijke Philips NV trades at $26.85 (market cap $26.58B). The key difference: Koninklijke Philips NV pays a 3.75% dividend while JPMorgan Equity Premium Income ETF pays none, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.
| JEPI | PHG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $32.91 |
52-Week Low | $55.29 | $25.02 |
Market Cap | — | $26.58B |
Enterprise Value | — | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.
Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
